Company intelligence / Profile preview

Armistice Capital

New York, New York, USAarmisticecapital.com ↗
Ownership
Private
Development stage
Phase 2
01

Overview

Global hedge fund focused on value/event-driven investing primarily in healthcare/life sciences. No internal drug development programs but major investor across many public biotechs/pharmas.[1][2]

Industry
Investors
02

Drug pipeline

1 asset

Lomecel-B

Phase 2
Indications
Aging Frailty, Alzheimer's disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome, Hypoplastic Left Heart Syndrome

Beyond the preview

Go deeper on Armistice Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Armistice Capital.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call